IraMichaelTurnerMD

PubMed

• 1 citations
  AHS 2021 consensus on integrating new migraine therapies into clinical practice: Isn't our goal choice of best therapy regardless of cost?
  James A. Charles, Ira M. Turner> ;Headache. 2021 Nov 28
• 8 citations
  Timing and durability of response to erenumab in patients with episodic migraine.
  Peter J McAllister, Ira Turner, Uwe Reuter, Andrea Wang, James Scanlon, Jan Klatt, Denise E Chou, Gabriel Paiva da Silva Lima> ;Headache. 2021 Nov 1
• 10 citations
  Hypervigilance, Allostatic Load, and Migraine Prevention: Antibodies to CGRP or Receptor.
  Andrew M. Blumenfeld, Paul L. Durham, Alexander Feoktistov, Debbie L. Hay, Andrew F. Russo, Ira M. Turner> ;Neurology and Therapy. 2021 Jun 2
• 15 citations
  Patient-Reported Outcomes from a 1-Year, Real-World, Head-to-Head Comparison of OnabotulinumtoxinA and Topiramate for Headache Prevention in Adults With Chronic Migraine.
  Andrew M. Blumenfeld, Atul T. Patel, Ira M. Turner, Kathleen B Mullin, Aubrey Manack Adams, John F. Rothrock> ;Journal of Primary Care & Community Health. 2020 Sep 27
• 9 citations
  Effect of age on pharmacokinetics, efficacy, and safety of galcanezumab treatment in adult patients with migraine: results from six phase 2 and phase 3 randomized clin...
  Virginia L. Stauffer, Ira Turner, Phebe Kemmer, William Kielbasa, Kathleen Day, Martha Port, Tonya Quinlan, A. Camporeale> ;The Journal of Headache and Pain. 2020 Jun 23
• 22 citations
  Effect of a rescue or recurrence dose of lasmiditan on efficacy and safety in the acute treatment of migraine: findings from the phase 3 trials (SAMURAI and SPARTAN).
  Li Shen Loo, Brian M. Plato, Ira M. Turner, Michael Case, Joel Raskin, Sherie A. Dowsett, John H. Krege> ;BMC Neurology. 2019 Aug 13
• 37 citations
  An exploratory study of salivary calcitonin gene-related peptide levels relative to acute interventions and preventative treatment with onabotulinumtoxinA in chronic m...
  Roger Cady, Ira M. Turner, Kent Dexter, M.E. Beach, Ryan J. Cady, Paul L. Durham> ;Headache. 2014 Feb 1
• 123 citations
  OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline.
  Stephen D. Silberstein, Andrew M. Blumenfeld, Roger Cady, Ira M. Turner, Hans-Christoph Diener, Sheena K. Aurora, Mai D. Sirimanne, Ronald E. DeGryse, Catherine C. Tur...> ;Journal of the Neurological Sciences. 2013 Aug 15
• 7 citations
  A Cross‐Sectional Survey to Assess the Migraineur's Medication Decision‐Making Beliefs: Determining When a Migraine Is Triptan‐Worthy
  Stephen H. Landy, Ira M. Turner, M. Chris Runken, Mechele Lee, Ellen M Sulcs, Christopher F. Bell> ;Headache. 2013 Jul 1
• 6 citations
  Multi-Center Comparison of Response to a Single Tablet of Sumatriptan 85 mg and Naproxen 500 mg vs Usual Therapy Treating Multiple Migraine Attacks as Measured by the ...
  Roger Cady, Jim Banks, Robert Nett, Jerome Goldstein, Nathan L. Bennett, Ira M. Turner, Gary E. Ruoff, Stephen H. Landy, Kathleen Farmer, Márta Juhász, Jeanne Tarrasch...> ;Headache. 2011 Jun 1
• Headache and sexual activity: a review.
  Turner, I.M., Harding, T.M.> ;Headache. 2008-09-01
• 2 citations
  Migraine, botulinum toxin type-A, and the disappearing sebaceous cyst.
  Ira M. Turner, Tiffany Agrillo> ;Headache. 2005 Feb 1
• Painful Postganglionic Horners Syndrome Caused by Ethmoid Sinusitis
  Ira M. Turner, Stephen M. Newman, Tiffany Agrillo> ;Headache. 2004 Sep 1
• Trigeminal autonomic cephalalgia: a new variant?
  Ira M. Turner> ;Headache. 2003 Apr 1
• 20 citations
  Pharmacological prophylaxis against the development of kindled amygdaloid seizures
  Ira M. Turner, Stephen M. Newman, Sydney Louis, Henn Kutt> ;Annals of Neurology. 1977 Sep 1
• Join now to see all